...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients
【24h】

A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients

机译：低剂量氨基谷氨酰胺与氢化可的松联合或不联合氢化可的松对绝经后乳腺癌患者内分泌作用的比较

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The endocrine effects of 125 mg (low dose) aminoglutethimide (AG) twice daily (b.d.) were compared with those of 125 mg AG + 20 mg hydrocortisone (HC) b.d. in 23 and 45 postmenopausal patients with advanced breast cancer, respectively. The patients in each group were drawn from two separate populations, but the mean age and weight of the groups were similar and there were no significant differences between the pretreatment serum levels of the hormones investigated. Serum oestrone and oestradiol levels were suppressed by both treatments, but there was a significantly greater suppression by AG + HC. This greater suppression is probably due to the observed increase in serum androstenedione (i.e. precursor) levels with AG alone, whilst with AG + HC these levels were found to be reduced. In terms of suppression of serum oestrogen levels it is of benefit to combine low dose AG with HC.
机译：将每天两次（每日两次）125毫克（低剂量）氨基谷氨酰胺（AG）的内分泌作用与每天125毫克AG + 20毫克氢化可的松（HC）的内分泌作用进行比较。分别在23名和45名绝经后晚期乳腺癌患者中出现。每组患者均来自两个不同的人群，但各组的平均年龄和体重相似，并且所研究激素的治疗​​前血清水平之间无显着差异。两种治疗均抑制了血清雌酮和雌二醇的水平，但AG + HC的抑制作用明显更大。这种更大的抑制作用可能是由于观察到单独使用AG时血清雄烯二酮（即前体）水平增加，而使用AG + HC时发现这些水平降低了。就抑制血清雌激素水平而言，将低剂量AG与HC结合使用是有益的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号